What is Liraglutide?
Liraglutide is a synthetic peptide that closely mimics a natural hormone called GLP-1 — short for glucagon-like peptide-1. Your gut releases GLP-1 after you eat. It tells your body to produce insulin, slow digestion, and feel full. Liraglutide is engineered to do the same job, but it lasts much longer in the body than the natural hormone does.[6] In the research world it is also known by its brand names Victoza and Saxenda, developed at different dose levels for different study purposes. On this reference page, it is treated strictly as a research compound — not a product for personal use.
How Liraglutide Works
Think of GLP-1 receptors as locks scattered around your body — on pancreas cells, in the gut, and critically, inside the brain. Liraglutide is the key that fits those locks.
When it turns the lock in the pancreas, insulin is released and blood sugar falls. When it turns the lock in the gut, digestion slows and you feel full sooner. The brain piece is especially interesting to researchers. Studies in animals show that liraglutide can actually cross into a region of the hypothalamus called the arcuate nucleus (ARC). There it activates appetite-suppressing neurons (POMC/CART neurons) while quieting hunger-promoting neurons (NPY/AgRP neurons) — a double hit on appetite.[2] That brain action is now believed to be a major driver of the weight loss seen in research subjects.[2]
What the Research Shows
Weight loss and sleep apnea
A randomized clinical trial called SCALE Sleep Apnea enrolled people with obesity who also had moderate-to-severe obstructive sleep apnea (OSA) — a condition where breathing repeatedly stops during sleep. After 32 weeks, participants using liraglutide lost significantly more body weight than those on placebo (about 5.7% vs 1.6%). Crucially, the number of breathing interruptions per hour (called the apnea-hypopnea index) also dropped more in the liraglutide group. Blood pressure and blood sugar markers improved too.[1] Researchers noted that a big chunk of the OSA improvement tracked directly with how much weight was lost.[1]
Fatty liver disease
Non-alcoholic fatty liver disease (NAFLD) is very common in people with type 2 diabetes. Lab research in mice found that liraglutide not only improved blood glucose but also reduced liver tissue damage. The proposed mechanism involves activating a cellular energy-sensing pathway called AMPK/ACC and blocking a type of cell death called ferroptosis — essentially protecting liver cells from a damaging chain reaction driven by fat oxidation.[3]
Heart failure research
A mouse-model study explored a form of heart failure called HFpEF (heart failure with preserved ejection fraction), which is tied to metabolic problems. Liraglutide, alone or combined with another compound, improved the heart's ability to relax between beats and reduced abnormal thickening of heart muscle. Researchers pointed to the Erbb4 signaling pathway as a possible explanation.[4]
Real-world adherence
A real-world study of commercially insured adults without diabetes who were prescribed GLP-1 receptor agonists for obesity found that long-term persistence — sticking with the treatment — was a significant challenge, which researchers say has implications for understanding outcomes in this drug class.[5]
What Liraglutide Is Being Studied For
- Glycemic (blood sugar) control in type 2 diabetes models[3]
- Weight reduction in obesity[1][6]
- Obstructive sleep apnea severity linked to obesity[1]
- Non-alcoholic fatty liver disease associated with diabetes[3]
- Heart failure with preserved ejection fraction (HFpEF) in animal models[4]
- Weight regain after bariatric (metabolic) surgery
- Pediatric obesity (children aged 6 to under 12)
How Liraglutide Is Dosed in Research
Research protocols have used a range of doses depending on the goal — from 1.2 mg per day in glycemic-control studies to 3 mg per day in obesity and weight-loss trials, with treatment durations ranging from 30 weeks to over a year.[6] Rather than repeating every number here, the full breakdown — including pediatric obesity, post-bariatric surgery, and adult weight-loss protocols — is laid out clearly in the dosage chart on this page. You can also use the calculator to explore how doses scale by body weight in preclinical models. Remember: these figures are reference data for research purposes only.
Mixing and Storing Liraglutide
Liraglutide for research is typically supplied either as a pre-dissolved solution or as a lyophilized (freeze-dried) powder. If you receive a powder, it is generally reconstituted using sterile bacteriostatic water — add the liquid slowly down the side of the vial and swirl gently; never shake vigorously, as this can break down the peptide structure. Once dissolved, research-grade liraglutide solutions are typically stored refrigerated at 2–8 °C and shielded from direct light. Most suppliers recommend using the reconstituted solution within 30 days. Always follow the specific handling instructions provided with your research-grade material, and use standard aseptic technique throughout. These handling notes are general guidance for laboratory research settings only.
Sources
- Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. — International journal of obesity (2005), 2016. PMID 27005405.
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. — The Journal of clinical investigation, 2014. PMID 25202980.
- Liraglutide attenuates type 2 diabetes mellitus-associated non-alcoholic fatty liver disease by activating AMPK/ACC signaling and inhibiting ferroptosis. — Molecular medicine (Cambridge, Mass.), 2023. PMID 37770820.
- Empagliflozin and liraglutide ameliorate HFpEF in mice via augmenting the Erbb4 signaling pathway. — Acta pharmacologica Sinica, 2024. PMID 38589689.
- Real-world persistence and adherence to glucagon-like peptide-1 receptor agonists among obese commercially insured adults without diabetes. — Journal of managed care & specialty pharmacy, 2024. PMID 38717042.
- Liraglutide (Saxenda) for Weight Loss. — American family physician, 2016. PMID 27419334.
EN
BR
ES
FR
DE
RU